Patent Landscape Report on Ritonavir - WIPO

ContentsExecutive Summary ................................................................................................................ 7Section 1 - Introduction ........................................................................................................... 9Section 2 – Search Process.................................................................................................. 102.1 Introduction.................................................................................................................. 102.2 Explanation of Search History and Methodology ........................................................ 10Section 3 - Statistical Analysis .............................................................................................. 163.1 Introduction.................................................................................................................. 163.2 Results 16Section 4 - Analysis of Innovation Tracks and Patterns of Continued Protection ................. 334.1 Introduction.................................................................................................................. 334.1.1 Methodology for determining innovation tracks .................................................... 334.1.2 Brief description of innovation tracks .................................................................... 364.2 Analysis of Innovation Tracks...................................................................................... 394.2.1 Innovation track 1: Liquid Oral Dosage Forms* .................................................... 394.2.2 Innovation track 2: Synthesis of Ritonavir* ........................................................... 424.2.3 Innovation track 3: Structural Considerations and Polymorphs*........................... 454.2.4 Innovation track 4: Solid Dosage Forms* ............................................................. 484.2.5 Innovation track 5: Prodrugs of Ritonavir* ............................................................ 514.3 Summary .....................................................................................................................57Section 5 - <strong>Report</strong> Summary................................................................................................. 58Appendix 1 - Innovation Tracks ............................................................................................ 601.1 Liquid Oral Dosage Forms .......................................................................................... 601.2 Synthesis of Ritonavir.................................................................................................. 611.3 Polymorphs ................................................................................................................. 621.4 Solid Dosage Forms.................................................................................................... 631.5 Prodrugs of Ritonavir................................................................................................... 64Appendix 2 - Glossary of Important Terms and Concepts .................................................... 65Search Operators .............................................................................................................. 65Dictionary .......................................................................................................................... 65Appendix 3 – Ritonavir <strong>Patent</strong> Database Description ........................................................... 68Appendix 4 - Search History ................................................................................................. 69Minesoft Patbase Search History ...................................................................................... 69Total <strong>Patent</strong> ....................................................................................................................... 96Thomson Innovation.......................................................................................................... 98